Illumina will process over 6,500 samples for the Type 1 Diabetes Genetics Consortium (T1DGC) via its FastTrack Genotyping Services. T1DGC is attempting to identify genes that influence an individual’s risk for developing type 1 diabetes.


“Illumina’s technology meets the University of Virginia’s needs in terms of data quality, call rates, and genomic coverage, and we think that provides us with the most potential for discovering variants linked to complex disease like type 1 diabetes,” says Stephen Rich, Ph.D., principal investigator from the University of Virginia and chair of the T1DGC steering committee.